Lynparza fails a PhIII test in colorectal cancer, cutting off big R&D avenue for Merck and AstraZeneca
As AstraZeneca and Merck look to continue building out their Lynparza franchise, one cancer type is proving too tough a nut to crack.
The Big …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
